Clinical trials: Hospitalized Adult Patients
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diarrhea, Clostridium Infections
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
The purpose of this study is to evaluate the efficacy and safety of Bio-K + CL1285 versus placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients.
- Trial name
- NCT00328263
- Testing
- Lactobacillus acidophilus CL1285 and Lactobacillus casei
- Where
- 8 sites in Canada
- Volunteers
- 472 people
- Sponsor
- Bio-K Plus International Inc.
COVID-19 Infection
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting.
- Trial name
- CRISIS2 (NCT04575038)
- Testing
- Brequinar
- Where
- 14 sites in United States
- Volunteers
- 115 people
- Sponsor
- Clear Creek Bio, Inc.
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Covid19, Sepsis
Feasibility Study of Hematology Parameters in COVID-19 Disease
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or…
- Conditions
- Covid19, Sepsis, Adults, Emergency Department
- Trial name
- NCT04816630
- Testing
- CBC-Diff Monocyte Volume Width Distribution
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beckman Coulter, Inc.
Soft Tissue Infections
A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization.
- Trial name
- NCT00303589
- Testing
- Standard care, beta-lactam
- Where
- 62 sites in United States, Argentina and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
COVID-19 Pneumonia
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314
A Double-blind, Multi-center, Multi-regional, Randomized controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19
- Trial name
- NCT04871646
- Testing
- CKD-314+SOC
- Where
- South Korea
- Volunteers
- 586 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Covid19
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19
This is a placebo-controlled study to investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults with COVID-19.
- Trial name
- NCT04771351
- Testing
- COVI-AMG
- Where
- United States
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.
- Trial name
- NCT04709835
- Testing
- AT-527
- Where
- 12 sites in Canada, Greece and 4 more
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04628143
- Testing
- Nafamostat Mesilate
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Covid19
Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19
This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Novaferon, in hospitalized adult patients diagnosed with COVID-19.
- Trial name
- NOVATION-1 (NCT04669015)
- Testing
- Novaferon
- Where
- 88 sites in Argentina, Brazil and 10 more
- Volunteers
- 914 people
- Sponsor
- Genova Inc.
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience
Schizophrenia
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
This is a Phase 2, randomized, double-blinded, placebo-controlled, inpatient study to examine the efficacy, safety, and tolerability profile of KarXT in adult subjects diagnosed with DSM-5 schizophrenia who are in an acute…
- Trial name
- EMERGENT-1 (NCT03697252)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 12 sites in United States
- Volunteers
- 182 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Influenza A H3N2, Influenza A H1N1
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza, or the flu, is an infectious respiratory disease that can range in severity from mild to severe to even death. This study aims to evaluate a treatment for people who are hospitalized with the flu.
- Trial name
- NCT03315104
- Testing
- FLU-IGIV
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- Emergent BioSolutions
Covid19
Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
- Trial name
- NCT05172037
- Testing
- Novaferon
- Where
- Japan
- Volunteers
- 222 people
- Sponsor
- Genova Inc.
Influenza
Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients
The objective of the study is virological assessment (e.g., proportion of prolonged viral shedding, median days to viral clearance, and viral load) in laboratory-confirmed adult influenza patients admitted to the general ward…
- Trial name
- NCT01839760
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- Crucell Holland BV